Equities UK Pharmaceuticals & Health

Smith & Nephew share price: Group wraps up Brainlab deal

Share this article!

Smith & Nephew (LON:SN) has wrapped up the acquisition of the Brainlab orthopaedic joint reconstruction business, the blue-chip company has said. The move came after the artificial hips and knees maker recently inked a deal to buy NASDAQ-listed Osiris Therapeutics for $660 million in cash.

Smith & Nephew’s share price has been subdued in London this morning, having shed 0.48 percent to 1,656.00p as of 08:06 BST. The stock, however, is marginally outperforming the broader UK market, with the benchmark FTSE 100 index currently standing 0.82 percent lower at 7,103.02 points. The group’s shares have added more than 21 percent of their value over the past year, as compared with about a seven-percent fall in the Footsie.

S&N wraps up Brainlab deal

Smith & Nephew announced in a statement this morning that it had completed the acquisition of the Brainlab orthopaedic joint reconstruction business. The blue-chip group said that the acquisition supported its strategy to invest in technologies which further its digital surgery and robotic ecosystem.

Smith & Nephew noted that its initial priority will be to integrate the Brainlab technology into NAVIO 7.0, the next version of its surgical robotics system. The companies are further collaborating  on developing additional applications to enhance the FTSE 100 group’s digital surgery ecosystem.

The commercial terms of the acquisition have not been disclosed.

Analysts on FTSE 100 group

JPMorgan Chase & Co, which rates the FTSE 100 group as a ‘neutral,’ boosted its target on the Smith & Nephew share price from 1,689p to 1,758p. According to MarketBeat, the artificial hips and knees maker currently has a consensus ‘hold’ rating and an average price target of 1,506.50p.

Smith & Nephew updated investors on its first-quarter performance last month, posting a 4.4-percent rise in organic revenue on an underlying basis and flagged revenue growth in the upper half of the guidance range.

Add Comment

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.